Complete remission (no further aphthous episodes to 6 months) · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 6 months: partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete or partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ Sustained remission/steroid sensitive relapses Clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: sustained… compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ CKD clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: CKD compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
FVC (% predicted) Change from baseline · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Adverse effects: anaemia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: anaemia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Thrombocytopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: thrombocytopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
All‐cause mortality 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in all‐cause mortality 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with placebo (low certainty).
1 finding from 1 review
Adverse events: haematuria 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: haematuria 12‐month compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
All‐cause mortality 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in all‐cause mortality 12‐month compared with placebo (low certainty).
1 finding from 1 review
FVC (% predicted) Change from baseline · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review